BCL2L1 and plasma cell myeloma: Another study demonstrated that an immature plasma cell phenotype in myeloma patients with t(11;14) consisting of significantly low CD38 and CD138 expression and high levels of B-cell markers such as CD79A and PAX5, along with an increased BCL2/BCL2L1 ratio, was highly susceptible to venetoclax treatment and less sensitive to daratumumab-based therapies, supporting further the hypothesis that venetoclax sensitivity is predicted by a robust B-cell myeloma phenotype (84).